HealthMed Holdings completed validation on a blood test that aims to identify individuals who are at risk of a heart attack and may be missed by conventional tests.Â
These individuals have no symptoms and frequently have normal standard blood cholesterol profiles, but are at significant risk of having a heart attack in the near term. The group is actively commercializing the test.
